2022-RA-1194-ESGO Efficacy of dostarlimab in endometrial cancer by molecular subtype: a post hoc analysis of the GARNET study. (20th October 2022)

• Record Type: Journal Article
• Authors: Tinker, Anna V; Pothuri, Bhavana; Gilbert, Lucy; Sabatier, Renaud; Brown, Jubilee; Ghamande, Sharad; Mathews, Cara; O'Malley, David M; Boni, Valentina; Gravina, Adriano; Banerjee, Susana; Miller, Rowan E; Pikiel, Joanna; Mirza, Mansoor R; Duan, Tao; Han, Xinwei; Zildjian, Sybil; Zografos, Eleftherios; Veneris, Jennifer; Oaknin, Ana
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 2
• Page Start: A413
• Page End: A413
• Publication Date: 2022-10-20
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-ESGO.885
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: Biomarkers are used to classify endometrial cancer (EC) into molecular subtypes such as TCGA and/or a surrogate classification (POLε mutated [mut], mismatch repair/microsatellite instability [MMR/MSI], TP53mut, and no specific mutation profile [NSMP]) or by estrogen receptor (ER) status. Here, we report on a post hoc analysis of objective response rate (ORR) by a surrogate classification for EC in patients receiving dostarlimab monotherapy. Methodology: GARNET is a multicentre, open-label, single-arm phase 1 study. Patients were assigned to cohort A1 (MMR deficient/MSI-high [dMMR/MSI-H EC]) or A2 (MMR proficient/microsatellite stable [MMRp/MSS] EC) based on local assessment. Patients received 500 mg of dostarlimab IV Q3W for 4 cycles, then 1000 mg Q6W until disease progression, discontinuation, or withdrawal. The primary endpoints were ORR and duration of response by blinded independent central review. Molecular subtype was determined by POLε and TP53 mutation status by Foundation Medicine, and MMR/MSI status was determined by local immunohistochemistry or next-generation sequencing; all others were assigned as NSMP. The hierarchy for classification was POLεmut → MMR/MSI → TP53 status → NSMP. ER status was determined by local immunohistochemistry testing. Only patients with samples available for additional biomarker testing were included in the biomarker assessment. Results: 143 patients with dMMR/MSI-H EC and 156 patients with MMRp/MSS were included in the efficacy-evaluable population. ORRs were determined for molecular subtypes and ER expression ( table 1 ). Safety has been previously reported. Conclusion: The observed ORRs in each molecular subgroup were consistent with the overall ORR in each cohort. Differences by ER expression status were not observed. These findings support the importance of testing patients with EC for MMR/MSI biomarker status as a predictor of response. Additionally, data suggest that TP53 mutation or ER expression should not modify treatment approach. The data are of interest for hypothesis generation.